Vaccine | Exposure windows | Number of studies | Vaccine exposure group (total, n) | Vaccine exposure group (SA, n) | Control group (total, n) | Control group (SA, n) | RR | 95% CI | I 2 | RD (%) | 95% CI (%) | I 2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2vHPV | Pre-90 days to pregnancy end | 3 | 1176 | 155 | 4308 | 521 | 1.15 | 0.95–1.39 | 0.0 | 1.6 | −0.8-4.1 | 0.0 |
Pre-45 days to pregnancy end | 2 | 680 | 85 | 1046 | 99 | 1.28 | 0.96–1.70 | 0.0 | 2.7 | −0.7-6.1 | 0.0 | |
Pre-45 days to LMP | 1 | 317 | 48 | 316 | 30 | 1.59 | 1.04–2.45 | – | 5.6 | 0.2–11.1 | – | |
During pregnancy (0–12 GWs) | 1 | 137 | 16 | 124 | 17 | 0.85 | 0.45–1.61 | – | −2.0 | −10.7-6.6 | – | |
4vHPV | Pre-45 days to pregnancy end | 4 | 2557 | 238 | 4257 | 389 | 0.88 | 0.73–1.06 | 0.0 | −1.3 | −2.9-0.3 | 0.0 |
Pre-45 days to LMP | 3 | 1199 | 141 | 2405 | 276 | 1.00 | 0.80–1.24 | 0.0 | 0.1 | −2.5-2.7 | 0.0 | |
During pregnancy | 2 | 1358 | 97 | 2771 | 209 | 0.79 | 0.62–1.01 | 0.0 | −1.8 | −3.5-0.1 | 0.0 | |
9vHPV | Pre-30 days to first 30 days of pregnancy | 1 | 97 | 17 | 1418 | 122 | 2.04 | 1.28–3.24 | – | 8.9 | 1.2–16.6 | – |